Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Encysive Pharmaceuticals logo — Leading the fight against vascular and inflammatory diseases...

Encysive Pharmaceuticals

Leading the fight against vascular and inflammatory diseases with groundbreaking synthetic and small molecule compounds.

Founded 1989 Private Equity Total: $88.95M Biotechnology, Pharmaceutical

General Information

Company Name Encysive Pharmaceuticals
Founded Year 1989
Industries Biotechnology, Pharmaceutical
Funding Stage Private Equity
Social

BounceWatch is an independent company data service, not affiliated with Encysive Pharmaceuticals. To contact Encysive Pharmaceuticals, visit encysive.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Encysive Pharmaceuticals compare?

A PDF of Encysive Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Encysive Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Encysive Pharmaceuticals

Encysive Pharmaceuticals, Inc. is a pioneering biopharmaceutical company focused on combatting vascular and inflammatory diseases through the development and commercialization of synthetic and small molecule compounds. The company's dedication to research and development is evident in its range of products, including Argatroban for treating heparin-induced thrombocytopenia, and Thelin (sitaxsentan sodium), designed to address pulmonary arterial hypertension, congestive heart failure, and essential hypertension. The clinical development pipeline features promising candidates such as TBC3711, TBC4746, ENC8003, and bimosiamose, targeting various receptors and conditions. Established in 1989 as Texas Biotechnology Corporation and rebranded to Encysive Pharmaceuticals, Inc. in 2003, the company has solidified research collaborations and licensing agreements with industry giants like GlaxoSmithKline plc, Mitsubishi Pharma Corporation, Schering-Plough, Ltd., Schering Corporation, and Revotar Biopharmaceuticals, AG. Notably, Encysive Pharmaceuticals received a significant $13.95MPrivate Equity Round investment on 20 August 2007, led by Enable Capital Management and Hudson Capital Group. Based in Houston, Texas, Encysive Pharmaceuticals, Inc. operated as a subsidiary of Pfizer Inc. as of June 10, 2008. The company's commitment to addressing critical medical needs and strategic collaborations positions it as a contender in the biotechnology and pharmaceutical industries.

Business keywords: biopharmaceutical company, medical research, vascular diseases, inflammatory diseases, small molecule compounds, endothelin receptor antagonist, clinical development, therapeutic compounds, collaboration agreements, Pulmonary arterial hypertension, global medical needs, drug discovery, medical innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round $13.95M 2
Enable Capital Management
Enable Capital Management, Hudson Capital Group
20 Aug 2007
Private Equity Round $75.00M 1
Azimuth Opportunity
19 Oct 2006

Encysive Pharmaceuticals Alternatives & Competitors

View All Alternatives
Encysive Pharmaceuticals vs
Pharmacopeia
Pharmacopeia

Innovating to meet critical health challenges with advanced therapeutic discoveries and developments...

Venture round
Biopharma, Biotechnology
Encysive Pharmaceuticals vs
Synta Pharmaceuticals
Synta Pharmaceuticals

Innovating patient care with advanced small molecule therapies for severe medical conditions, includ...

Post-IPO Equity
Biotechnology, Health Care
Encysive Pharmaceuticals vs
ORIC Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc. United States

Overcoming Resistance In Cancer

Post-IPO Equity
119 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Encysive Pharmaceuticals

Leading the fight against vascular and inflammatory diseases with groundbreaking synthetic and small molecule compounds.
Encysive Pharmaceuticals was founded in 1989.
Encysive Pharmaceuticals operates in Biotechnology and Pharmaceutical. Its work centres on biopharmaceutical company, medical research, vascular diseases and inflammatory diseases.
Encysive Pharmaceuticals has completed 2 funding rounds, raising a total of $88.95M. The latest funding stage is Private Equity.
Top alternatives and competitors to Encysive Pharmaceuticals include Pharmacopeia, Synta Pharmaceuticals, ORIC Pharmaceuticals Inc., Chance Pharmaceuticals 畅溪制药, Realm Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Encysive Pharmaceuticals and Pharmacopeia are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Encysive Pharmaceuticals, https://bouncewatch.com/company/encysive-pharmaceuticals, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout